NO20010747L - Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff - Google Patents

Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff

Info

Publication number
NO20010747L
NO20010747L NO20010747A NO20010747A NO20010747L NO 20010747 L NO20010747 L NO 20010747L NO 20010747 A NO20010747 A NO 20010747A NO 20010747 A NO20010747 A NO 20010747A NO 20010747 L NO20010747 L NO 20010747L
Authority
NO
Norway
Prior art keywords
von willebrand
willebrand factor
monoclonal antibody
humanized anti
antithrombotic agent
Prior art date
Application number
NO20010747A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010747D0 (no
Inventor
Man Sung Co
Maximiliano Vasquez
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of NO20010747D0 publication Critical patent/NO20010747D0/no
Publication of NO20010747L publication Critical patent/NO20010747L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20010747A 1998-08-19 2001-02-14 Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff NO20010747L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/136,315 US6228360B1 (en) 1998-08-19 1998-08-19 Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
PCT/US1999/016724 WO2000010601A1 (en) 1998-08-19 1999-08-19 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody

Publications (2)

Publication Number Publication Date
NO20010747D0 NO20010747D0 (no) 2001-02-14
NO20010747L true NO20010747L (no) 2001-04-03

Family

ID=22472317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010747A NO20010747L (no) 1998-08-19 2001-02-14 Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff

Country Status (17)

Country Link
US (4) US6228360B1 (pt)
EP (1) EP1112085B1 (pt)
JP (1) JP4590734B2 (pt)
KR (1) KR100693260B1 (pt)
CN (1) CN1259972C (pt)
AT (1) ATE476989T1 (pt)
AU (1) AU766500B2 (pt)
BR (1) BR9913084A (pt)
CA (1) CA2340466A1 (pt)
DE (1) DE69942668D1 (pt)
HU (1) HUP0103573A3 (pt)
IL (2) IL141158A0 (pt)
NO (1) NO20010747L (pt)
NZ (1) NZ509536A (pt)
RU (1) RU2223785C2 (pt)
WO (1) WO2000010601A1 (pt)
ZA (1) ZA200100939B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228360B1 (en) 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
AU2002335815A1 (en) * 2001-10-16 2003-04-28 Rxkinetix, Inc. High-concentration protein formulations and method of manufacture
JP2005298336A (ja) * 2002-01-29 2005-10-27 Ajinomoto Co Inc 炎症性疾患治療用薬剤
WO2004011030A1 (ja) * 2002-07-29 2004-02-05 Ajinomoto Co., Inc. 血小板減少症治療用医薬組成物
ATE512364T1 (de) * 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
EP1587838B1 (en) 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
EP1755642B1 (en) * 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin v for preventing plaque rupture
CA2579374A1 (en) * 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
US20090202986A1 (en) * 2004-10-22 2009-08-13 Huse William D Methods of optimizing antibody variable region binding affinity
WO2006074947A2 (en) * 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
KR101414438B1 (ko) * 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
JP2011518772A (ja) * 2008-03-21 2011-06-30 アブリンクス エン．ヴェー． フォンウィルブランド因子特異的結合因子及びこれらに関する使用方法
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010091231A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102532316B (zh) * 2010-12-24 2014-06-18 神州细胞工程有限公司 一种抗vWF单克隆抗体及其应用
WO2015158851A1 (en) * 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ZA93779B (en) * 1992-02-06 1993-08-05 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
EP0625200B1 (en) * 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ATE236993T1 (de) * 1994-11-30 2003-04-15 Ajinomoto Kk Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody

Also Published As

Publication number Publication date
RU2223785C2 (ru) 2004-02-20
AU766500B2 (en) 2003-10-16
EP1112085A4 (en) 2002-11-20
KR100693260B1 (ko) 2007-03-13
US20030180293A1 (en) 2003-09-25
US20030064068A1 (en) 2003-04-03
DE69942668D1 (de) 2010-09-23
JP2002523379A (ja) 2002-07-30
HUP0103573A2 (hu) 2002-01-28
BR9913084A (pt) 2001-05-08
KR20010072749A (ko) 2001-07-31
US6613328B2 (en) 2003-09-02
ZA200100939B (en) 2001-09-03
CN1259972C (zh) 2006-06-21
NO20010747D0 (no) 2001-02-14
JP4590734B2 (ja) 2010-12-01
HUP0103573A3 (en) 2003-09-29
IL141158A (en) 2006-04-10
AU5668099A (en) 2000-03-14
NZ509536A (en) 2002-11-26
EP1112085A1 (en) 2001-07-04
CN1311691A (zh) 2001-09-05
CA2340466A1 (en) 2000-03-02
US6228360B1 (en) 2001-05-08
IL141158A0 (en) 2002-02-10
US7138116B2 (en) 2006-11-21
US7311913B2 (en) 2007-12-25
US20050197494A1 (en) 2005-09-08
ATE476989T1 (de) 2010-08-15
WO2000010601A1 (en) 2000-03-02
EP1112085B1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
NO20010747L (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
DK0724456T3 (da) CD40-Antistoffer
NO2017040I2 (no) Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC
RS53984B1 (en) IP-10 ANTIBODIES AND THEIR USES
PT973550E (pt) Anticorpos antagonistas anti-integrina avb3
ATE218387T1 (de) Antikörperreinigung
EE200100336A (et) CTLA-4 vastased inimese monoklonaalsed antikehad
EE05627B1 (et) CTLA-4 vastased inimese monoklonaalsed antikehad
HRP20000714B1 (en) NOVEL CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
BR0015872A (pt) Agentes antitrombóticos
DE69527868T2 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
GR3030212T3 (en) Platelet activating factor antagonists.
BR1100555B1 (pt) anticorpos monoclonais humanizados.
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk